Compound: Nisoxetine
SMILES: O(c1c(OC)cccc1)C(c2ccccc2)CCNC
InChIKey: ITJNARMNRKSWTA-UHFFFAOYSA-N
Synonyms: Nisoxetine, 53179-07-0, 3-(2-methoxyphenoxy)-N-methyl-3-phenylpropan-1-amine, Nisoxetina, Compound 89218, Nisoxetinum, 3-(2-Methoxyphenoxy)-N-methyl-3-phenylpropylamine, COMPOUND-89218, NSC-283481, DTXSID0045175, 17NV064B2D, DL-N-Methyl-3-(o-methoxyphenoxy)-N-methyl-3-phenylpropylamine, 3-(o-Methoxyphenoxy)-N-methyl-3-phenylpropylamine, N-Methyl-gamma-(2-methylphenoxy)phenylpropanolamine, DTXCID8025175, CHEBI:73410, LY 94939, RefChem:854206, 57226-61-6, CHEMBL295467, Benzenepropanamine, gamma-(2-methoxyphenoxy)-N-methyl-, Compound 89218; NSC 283481, NCGC00015715-04, Nisoxetine Inhibitor, Nisoxetine [USAN:INN], CAS-53179-07-0, UNII-17NV064B2D, NSC 283481, NISOXETINE [INN], Nisoxetine (USAN/INN), Prestwick0_000910, Prestwick1_000910, Prestwick2_000910, Prestwick3_000910, NISOXETINE [USAN], Lopac0_000901, BSPBio_000760, SCHEMBL124289, SPBio_002959, BPBio1_000836, GTPL4637, orb1740335, SCHEMBL29401038, BDBM22417, HMS2089K13, EX-A9581, Tox21 110203, Tox21_110203, NSC283481, PDSP1_000507, PDSP2_000505, Tox21_110203_1, CCG-204983, DB09186, SDCCGSBI-0050876.P002, NCGC00015715-03, NCGC00015715-05, NCGC00015715-06, NCGC00015715-08, NCGC00015715-15, NCGC00024945-02, NCGC00024945-03, AS-16468, DA-56190, AB00514644, NS00002148, D05173, AB00514644-07, N-methyl 3(o-methoxyphenoxy)-3-phenylpropylamine, N-methyl 3-(o-methoxyphenoxy)-3-phenylpropylamine, Q906885, [3-(2-methoxyphenoxy)-3-phenylpropyl](methyl)amine, N-methyl-3-phenyl-3-(o-methoxyphenoxy)-propylamine, BRD-A95696066-003-03-9, BRD-A95696066-003-06-2, BRD-A95696066-003-13-8, (+/-)-3-(O-METHOXYPHENOXY)-N-METHYL-3-PHENYLPROPYLAMINE, BENZENEPROPANAMINE, .GAMMA.-(2-METHOXYPHENOXY)-N-METHYL-, (+/-)-
Theoretical properties:
molecular_formula: C17H21NO2
molecular_weight: 271.35 g/mol
exact_mass: 271.157228913 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 3
rotatable_bond_count: 7
heavy_atom_count: 20
topological_polar_surface_area: 30.5 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Nisoxetine is a secondary amino compound that is N-methyl-3-phenylpropan-1-amine substituted at position 3 by a 2-methoxyphenoxy group. It has a role as an antidepressant and an adrenergic uptake inhibitor. It is an aromatic ether and a secondary amino compound.
chebi: A secondary amino compound that is <em>N</em>-methyl-3-phenylpropan-1-amine substituted at position 3 by a 2-methoxyphenoxy group.
chembl: NISOXETINE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 2.0.
wikipedia: Nisoxetine (developmental code name LY-94939), originally synthesized in the Lilly research laboratories during the early 1970s, is a potent and selective inhibitor for the reuptake of norepinephrine (noradrenaline) into synapses. It currently has no clinical applications in humans, although it was originally researched as an antidepressant. Nisoxetine is now widely used in scientific research as a standard selective norepinephrine reuptake inhibitor. It has been used to research obesity and energy balance, and exerts some local analgesia effects.
Researchers have attempted to use a carbon-labeled form of nisoxetine for positron emission tomography (PET) imaging of the norepinephrine transporter (NET), with little success. However, it seems that tritium-labeled nisoxetine (3H-nisoxetine, 3H-NIS) is a useful radioligand for labeling norepinephrine uptake sites in vitro, which nisoxetine and other antagonists for NET are able to inhibit.